Novel and selective inhibitors of SRC family kinases


Novel compounds displaying high potency and selectivity toward SRC family kinases have been developed. The lead compound eCF506 displays subnanomolar potency against SRC, high selectivity over ABL kinase (>1000-fold), optimal pharmacokinetic profile and in vivo target engagement.

Bile duct cancer is difficult to detect

APPLICATION

  • Oncology: combination therapies in advanced cancer disease
  • Diabetic eye disease
  • Neurodegenerative diseases

DEVELOPMENT STATUS

Lead optimisation

IP STATUS

Lead series chemistry is protected by a patent application

(WO 2016/185160 A1)

COMMERCIAL OFFERING

  • Collaborative research
  • Co-development
  • Licensing

OPPORTUNITY


SRC is a non-receptor tyrosine kinase, which is overexpressed and/or over-activated in many types of cancer. SRC has been shown to have a crucial role in many aspects of tumour growth and development, including proliferation, migration, invasion, angiogenesis, metastasis and resistance to chemotherapy. Increased expression and activity of SRC correlate with advanced malignancy and poor clinical prognosis. All current SRC inhibitors display potent activity against Abl1, which results in undesired side effects (such as cardiotoxicity) and lower anti-cancer activity in certain tumour types.

Novel compounds displaying high potency and selectivity toward SRC family kinases have been developed by combining ligand-based design and phenotypic screening in an iterative manner.

TECHNOLOGY


The preclinical candidate eCF506 inhibits SRC kinase at subnanomolar levels with very high selectivity over ABL (>1000-fold). The compound displays excellent drug-like physiochemical properties, and is orally bioavailable with excellent efficacy in cells (EC50 below 10 nM) and in vivo pharmacokinetic profile. Inhibition of SRC phosphorylation and downstream signaling (FAK, paxillin) following oral, iv and IP administration has been demonstrated in breast and colorectal cancer xenograft models.

Proof of concept experiments have been conducted in vitro and in vivo, in zebrafish and xenograft models of breast and colorectal cancer.

BENEFITS


  • High anti-proliferative and anti-invasive activity in various cancer cell lines
  • Improved Safety: no ABL inhibition liability, which is associated with cardiotoxicity
  • Good oral bioavailability, half-life, stability

 

PUBLICATION


Fraser et al. J. Med. Chem. 2016, 59, 4697−4710

Please note, header image is purely illustrative.

Source: image iStock©

Enquiry for: Novel and selective inhibitors of SRC family kinases

15 + 11 =

CONTACT US

1-7 Roxburgh Street

Edinburgh EH8 9TA

0131 650 9090

SITEMAP

Home                           About Us    

For Business               News and Events  

For Staff       

For Students

 

 

SIGN UP TO OUR NEWSLETTER

Join our conversation and stay up-to-date with the latest innovations, news and upcoming events

News

13 + 14 =

 
Contact Us | Freedom of Information | Cookie Policy | Privacy Statement | Terms and Conditions | Modern Slavery Act